Skip to main content

Articles

Page 125 of 155

  3. Authors: T Pap, A Wille, A Drynda, M Neumann, A Baier, A Cinski, S Gay and I Meinecke
    Citation: Arthritis Res Ther 2004 6(Suppl 3):98
    Content type: Poster presentation Published on:

    This article is part of a Supplement: Volume 6 Supplement 3

  16. Relapsing polychondritis (RP) is an autoimmune disease that affects extra-articular cartilage. Matrilin-1-induced relapsing polychondritis (MIRP) is a model for RP and is useful for studies of the pathogenic m...

    Authors: Ann-Sofie Hansson, Ã…sa CM Johansson and Rikard Holmdahl
    Citation: Arthritis Res Ther 2004 6:R484
    Content type: Research article Published on:

  18. Antibodies against intact type II collagen (CII) are a feature of rheumatoid arthritis (RA) but have limited diagnostic value. Here we assess whether either of the two major cyanogen bromide fragments of CII, ...

    Authors: Andrew D Cook, Robyn Gray, John Ramshaw, Ian R Mackay and Merrill J Rowley
    Citation: Arthritis Res Ther 2004 6:R477
    Content type: Research article Published on:

  20. The objective of the present study was to investigate whether treatment of articular cartilage with hyaluronidase and collagenase enhances histological and mechanical integration of a cartilage graft into a de...

    Authors: Jarno van de Breevaart Bravenboer, Caroline D In der Maur, P Koen Bos, Louw Feenstra, Jan AN Verhaar, Harrie Weinans and Gerjo JVM van Osch
    Citation: Arthritis Res Ther 2004 6:R469
    Content type: Research article Published on:

  21. This study aimed to evaluate the effects of hormone replacement therapy (HRT), known to prevent osteoporosis and fractures, on markers of bone and cartilage metabolism. Furthermore, we assessed whether changes...

    Authors: Helena Forsblad d'Elia, Stephan Christgau, Lars-Ã…ke Mattsson, Tore Saxne, Claes Ohlsson, Elisabeth Nordborg and Hans Carlsten
    Citation: Arthritis Res Ther 2004 6:R457
    Content type: Research article Published on:

  23. IL-18, an immunoregulatory and proinflammatory cytokine, has been shown to play an important pathogenic role in Th1-driven autoimmune disorders. In this study, we evaluated the circulating levels and salivary-...

    Authors: Michele Bombardieri, Francesca Barone, Valerio Pittoni, Cristiano Alessandri, Paola Conigliaro, Mark C Blades, Roberta Priori, Iain B McInnes, Guido Valesini and Costantino Pitzalis
    Citation: Arthritis Res Ther 2004 6:R447
    Content type: Research article Published on:

  27. The pathogenesis of chronic inflammatory joint diseases such as adult and juvenile rheumatoid arthritis and Lyme arthritis is still poorly understood. Central to the various hypotheses in this respect is the n...

    Authors: Vera Sobek, Nico Birkner, Ingrid Falk, Andreas Würch, Carsten J Kirschning, Hermann Wagner, Reinhard Wallich, Marinus C Lamers and Markus M Simon
    Citation: Arthritis Res Ther 2004 6:R433
    Content type: Research article Published on:

  28. We first identified and isolated cellular subpopulations with characteristics of mesenchymal progenitor cells (MPCs) in osteoarthritic cartilage using fluorescence-activated cell sorting (FACS). Cells from ost...

    Authors: Stefan Fickert, Jörg Fiedler and Rolf E Brenner
    Citation: Arthritis Res Ther 2004 6:R422
    Content type: Research article Published on:

  29. Estrogen and estrogen receptors (ERs) are known to play important roles in the pathophysiology of osteoarthritis (OA). To investigate ER-α gene polymorphisms for its associations with primary knee OA, we condu...

    Authors: Sheng-Yu Jin, Seung-Jae Hong, Hyung In Yang, Sang-do Park, Myung-Chul Yoo, Hee Jae Lee, Mee-Suk Hong, Hae-Jeong Park, Seo Hyun Yoon, Bum-Shik Kim, Sung-Vin Yim, Hun-Kuk Park and Joo-Ho Chung
    Citation: Arthritis Res Ther 2004 6:R415
    Content type: Research article Published on:

  30. Collagen-induced arthritis (CIA) is a chronic inflammatory disease bearing all the hallmarks of rheumatoid arthritis, e.g. polyarthritis, synovitis, and subsequent cartilage/bone erosions. One feature of the d...

    Authors: Hoang Tu-Rapp, André Hammermüller, Eilhard Mix, Hans-Jürgen Kreutzer, Roland Goerlich, Hansjürgen Köhler, Horst Nizze, Hans-Jürgen Thiesen and Saleh M Ibrahim
    Citation: Arthritis Res Ther 2004 6:R404
    Content type: Research article Published on:

  31. Insulin-like growth factor 1 (IGF-1) has poor anabolic efficacy in cartilage in osteoarthritis (OA), partly because of its sequestration by abnormally high levels of extracellular IGF-binding proteins (IGFBPs)...

    Authors: Frédéric De Ceuninck, Audrey Caliez, Laurent Dassencourt, Philippe Anract and Pierre Renard
    Citation: Arthritis Res Ther 2004 6:R393
    Content type: Research article Published on:

  35. In inflammatory processes, the p38 mitogen-activated protein kinase (MAPK) signal transduction route regulates production and expression of cytokines and other inflammatory mediators. Tumor necrosis factor α (...

    Authors: Johanna Westra, Berber Doornbos-van der Meer, Peter de Boer, Miek A van Leeuwen, Martin H van Rijswijk and Pieter C Limburg
    Citation: Arthritis Res Ther 2004 6:R384
    Content type: Research article Published on:

  37. A variety of cytokines and growth factors use the Janus kinase (Jak)–STAT signaling pathway to transmit extracellular signals to the nucleus. STATs (signal transducers and activators of transcription) are late...

    Authors: Lionel B Ivashkiv and Xiaoyu Hu
    Citation: Arthritis Res Ther 2004 6:159
    Content type: Review Published on:

  39. Ankylosing spondylitis (AS) is a member of the family of spondyloarthropathies, which are inflammatory arthritides largely involving the axial skeleton and commonly accompanied by peripheral arthritis. Genetic...

    Authors: Paul M Peloso and Jürgen Braun
    Citation: Arthritis Research & Therapy 2004 6(Suppl 2):S36
    Content type: Review Published on:

    This article is part of a Supplement: Volume 6 Supplement 2

  40. Psoriatic arthritis (PsA) is a seronegative spondyloarthropathy that commonly appears after the onset of the characteristic cutaneous lesions. This complication affects about 40% of patients with moderate to s...

    Authors: Alice B Gottlieb and Christian E Antoni
    Citation: Arthritis Research & Therapy 2004 6(Suppl 2):S31
    Content type: Review Published on:

    This article is part of a Supplement: Volume 6 Supplement 2

  41. Tumor necrosis factor (TNF) antagonists are biologic response modifiers that have significantly improved functional outcomes in patients with rheumatoid arthritis (RA). RA is a progressive disease in which str...

    Authors: David Yocum
    Citation: Arthritis Research & Therapy 2004 6(Suppl 2):S24
    Content type: Review Published on:

    This article is part of a Supplement: Volume 6 Supplement 2

  42. The tumor necrosis factor (TNF) antagonists are parenterally administered biologic response modifiers indicated for the management of rheumatoid arthritis. Although infliximab, etanercept, and adalimumab are a...

    Authors: Sergio Schwartzman and G James Morgan Jr
    Citation: Arthritis Research & Therapy 2004 6(Suppl 2):S19
    Content type: Review Published on:

    This article is part of a Supplement: Volume 6 Supplement 2

  43. Tumor necrosis factor (TNF) antagonists are biologic response modifiers that have significantly improved the outcomes in patients with rheumatoid arthritis (RA). At this report, safety data were collected on a...

    Authors: Roy Fleischmann and David Yocum
    Citation: Arthritis Research & Therapy 2004 6(Suppl 2):S12
    Content type: Review Published on:

    This article is part of a Supplement: Volume 6 Supplement 2

  44. Tumor necrosis factor (TNF) antagonists have dramatically improved the outcomes of rheumatoid arthritis (RA). Three agents currently available in the USA – infliximab, etanercept, and adalimumab – have been de...

    Authors: Sergio Schwartzman, Roy Fleischmann and G James Morgan Jr
    Citation: Arthritis Research & Therapy 2004 6(Suppl 2):S3
    Content type: Review Published on:

    This article is part of a Supplement: Volume 6 Supplement 2

  46. Rheumatoid arthritis (RA) is a common human disease with a prevalence of about 1% in most parts of the world. At the time of symptom onset it is difficult to predict the severity of subsequent disease course. ...

    Authors: Saleh Ibrahim and Ewa M Paleolog
    Citation: Arthritis Res Ther 2004 6:155
    Content type: Meeting report Published on:

  47. In the present study, we have shown for the first time that a plant steroid, diosgenin, causes an inhibition of the growth of fibroblast-like synoviocytes from human rheumatoid arthritis, with apoptosis induct...

    Authors: Bertrand Liagre, Pascale Vergne-Salle, Cecile Corbiere, Jean L Charissoux and Jean L Beneytout
    Citation: Arthritis Res Ther 2004 6:R373
    Content type: Research article Published on:

  48. This study was performed to determine the correlation between psychiatric manifestations and several autoantibodies that might participate in the pathogenesis of psychiatric disorders in the course of systemic...

    Authors: Fabrizio Conti, Cristiano Alessandri, Daniela Bompane, Michele Bombardieri, Francesca Romana Spinelli, Anna Carlotta Rusconi and Guido Valesini
    Citation: Arthritis Res Ther 2004 6:R366
    Content type: Research article Published on:

  49. Prostaglandin E synthase (PGES) including isoenzymes of membrane-associated PGES (mPGES)-1, mPGES-2, and cytosolic PGES (cPGES) is the recently identified terminal enzyme of the arachidonic acid cascade. PGES ...

    Authors: Fumiaki Kojima, Hiroaki Naraba, Satoshi Miyamoto, Moroe Beppu, Haruhito Aoki and Shinichi Kawai
    Citation: Arthritis Res Ther 2004 6:R355
    Content type: Research article Published on:

  50. Human T cell leukaemia virus type I (HTLV-I) is known to be involved in late-onset chronic polyarthritis as HTLV-I-associated arthropathy. However, it is unclear whether HTLV-I infection could modify the patho...

    Authors: Yoshiki Yoshihara, Tomoo Tsukazaki, Makoto Osaki, Masahiro Nakashima, Kazuhisa Hasui and Hiroyuki Shindo
    Citation: Arthritis Res Ther 2004 6:R347
    Content type: Research article Published on:
  • Logo
Submit manuscript

Follow

Annual Journal Metrics

  • Citation Impact 2023
    Journal Impact Factor: 4.4
    5-year Journal Impact Factor: 4.9
    Source Normalized Impact per Paper (SNIP): 1.294
    SCImago Journal Rank (SJR): 1.518

    Speed 2023
    Submission to first editorial decision (median days): 9
    Submission to acceptance (median days): 111

    Usage 2023
    Downloads: 3,331,819
    Altmetric mentions: 1,885

Arthritis Research & Therapy

ISSN: 1478-6362

Contact us